Extended Data Fig. 6: CYP3AHi persister phenotypes are associated with poor patient outcomes in mFFX but not GEM post-CTX patient samples.
From: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
a) Forest plot and associated table of discovery analyses showing univariate cox proportional hazards for post-CTX patient samples with the indicated dichotomized High and Low protein biomarker expression. Univariate analyses have not been corrected for multiple testing. Analyses are shown for combined GEM and mFFX (black) (n = 44), GEM alone (cyan) (n = 18) and mFFX alone (red) (n = 25) post-CTX patient samples. Hazard Ratios (HR) are shown on the plot as the central measure (symbol) with 95% Confidence Intervals (CI) shown as bars. Log-rank P-values (two-sided) and Median Overall Survival (MOS) for high and low expressing groups are provided for each comparison. Log-rank P-values were not adjusted for multiple testing. b) Kaplan Meier survival analysis for dichotomized High and Low CYP3A, ‘hybrid’ CYP3A/KRT17+ve and CYP3A/KRT17+ve persister phenotypes in post-CTX PDAC-HD samples. Kaplan Meier survival analysis of post-CTX patient samples representing combined (GEM and mFFX), GEM alone or mFFX alone is shown. Patient numbers for each group are provided under ‘Numbers at risk’. Log Rank P-value ≤ 0.05 is considered significant. Log-rank P-values were not adjusted for multiple testing.
